Bharat Biotech’s ‘Covaxin’ Gets Nod By SEC For Phase 2, 3 Trials On 2 to 18 Yrs | Catch News


Subject Expert Committee (SEC) gave nod to Bharat Biotech’s ‘Covaxin’ for phase 2 and 3 human clinical trials on 2 to 18 years. In the ongoing vaccination drive in India, the ‘Covaxin’ is being used in adults. ‘Covaxin’ is one of the two vaccines being manufactured in India currently and has been developed by Bharat Biotech.


#BharatBiotech​ #Covaxin​ #CovidVaccine​ #catchnews #CatchNewsToday

For more videos, subscribe to our channel: https://goo.gl/bkDSLj
Check out Catch News for more news: http://www.catchnews.com/

Follow Catch News here -
Facebook:https://bit.ly/2xD3NKZ
Twitter: https://bit.ly/2NG3rhr
Instagram: https://bit.ly/30mh2vE
--------------------------------------------------------------------------------------------
Also, Follow Catch in Hindi: http://hindi.catchnews.com/

Catch is a contemporary new digital platform about the ideas and events shaping the world. It aims to filter and provide news-on-the-run for an impatient new generation. It offers greater insight for influencers and the deeper consumer of news. When opinions are shrill and polarized, we hope to create a middle ground and build bridges. When there is a set thinking, we hope to stand apart and go against the wind. The world is complex, exciting, layered, evolving, always interesting. We hope to be the same.

Lots of videos and lots more in the pipeline. Stay tuned.

Bharat Biotech’s ‘Covaxin’ Gets Nod By SEC For Phase 2, 3 Trials On 2 to 18 Yrs | Catch News.